Tempus AI, Inc.

Listed Company
TEMCIK 0001717115NasdaqLarge AcceleratedServices-Computer Programming, Data Processing, Etc.NevadaFY ends Dec 31
Period
FY 2025
Revenue
$1.27B
Net Income
$-245.03M
Total Assets
$2.27B
Equity
$491.33M
Shares Out
Op. Cash Flow
$-218.09M

Business

Tempus AI, Inc. develops AI-driven Intelligent Diagnostics that connect laboratory results to patients’ clinical, molecular, and imaging data to personalize diagnostic insights and guide therapy selection. It offers Genomics testing (NGS, PCR, transcriptomic and methylation assays, liquid and tissue biopsies, hereditary screening), Data and Services (licensed de-identified multimodal datasets, analytics, clinical trial matching and organoid modeling), and AI Applications (algorithmic diagnostics and clinical decision support such as the Next platform and various Algos). Tempus operates a vertically integrated platform with proprietary software, laboratories, and data pipelines, and distributes services primarily through clinician ordering, provider integrations, and life sciences partnerships across the United States and select international collaborations.

Summary from filing dated 2025-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts
ConceptTrend
FY 2025
2025-12-31
FY 2024
2024-12-31
FY 2023
2023-12-31
FY 2022
2022-12-31
Total net revenue1,272693532321
Technology research and development1461689579
Research and development1731499083
Selling, general and administrative732755297233
Total cost and operating expenses1,5251,384728586
Loss from operations−253−691−196−265
Interest income131183
Interest expense−70−54−47−22
Loss on debt extinguishment−1200
Other income, net313222−5
Loss before benefit from (provision for) income taxes−291−701−214−289
benefit from (Provision for) income taxes52−266,000−288,000
losses from equity method investments−6−4−301,000−595,000
Net Loss−245−706−214−290
Accretion of convertible preferred stock to redemption value00−4−301,000
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares0−39−44−41
Cumulative undeclared dividends on Series C preferred shares0−1−3−3
Net loss attributable to common shareholders, basic−245−746−266−334
Net loss attributable to common shareholders, diluted−245−746−266−334
Net loss per share attributable to common shareholders, basic−1.41−6.23−4.2−5.3
Net loss per share attributable to common shareholders, diluted−1.41−6.23−4.2−5.3
Weighted-average shares outstanding used to compute net loss per share, basic174,264119,84963,30663,306
Weighted-average shares outstanding used to compute net loss per share, diluted174,264119,84963,30663,032
Foreign currency translation adjustment808,00089,000−13,00029,000
Comprehensive loss−244−706−214−290

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro